|

BEBT-209 capsules Clinical Trials

2 actively recruiting trials

No change since August 2026

Also known as: BEBT-209, KCBI-0191, KCBT-0191

Pipeline

Phase 3: 1Phase 2/3: 1

Top Sponsors

  • BeBetter Med Inc2

Indications

  • Breast Cancer2
  • Cancer2
  • HR+/HER2- Locally Advanced, Metastatic Breast Cancer1
  • Locally Advanced Triple-negative Breast Cancer1
  • Metastatic Triple-Negative Breast Cancer1

Other2 trials

A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Phase 2/3
Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.